TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:28
Amylyx Pharmaceuticals Inc. ( AMLX ) https://amylyx.com
4.07USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-72.41%
AMLX
SPY
32.66%
AMLX
0.00%
SPY
108.59%
AMLX
0.00%
SPY
302.52%
AMLX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
272.37
40.54
0.68
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.05
1.39
1.39
-46.70
0.00
-0.12
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-18187.74
-94.47
-394.31
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-231.31
-89.65
0.00
Other Earnings and Cash Flow Stats:
Amylyx Pharmaceuticals Inc. ( AMLX ) Net Income TTM ($MM) is -259.47
Amylyx Pharmaceuticals Inc. ( AMLX ) Operating Income TTM ($MM) is -272.14
Amylyx Pharmaceuticals Inc. ( AMLX ) Owners' Earnings Annual ($MM) is 0.00
Amylyx Pharmaceuticals Inc. ( AMLX ) Current Price to Owners' Earnings ratio is 0.00
Amylyx Pharmaceuticals Inc. ( AMLX ) EBITDA TTM ($MM) is -271.10
Amylyx Pharmaceuticals Inc. ( AMLX ) EBITDA Margin is -394.31%
Capital Allocation:
Amylyx Pharmaceuticals Inc. ( AMLX ) has paid 0.00 dividends per share and bought back 1.657101 million shares in the past 12 months
Amylyx Pharmaceuticals Inc. ( AMLX ) has reduced its debt by 2.201 million USD in the last 12 months
Capital Structure:
Amylyx Pharmaceuticals Inc. ( AMLX ) Interest-bearing Debt ($MM) as of last quarter is 2
Amylyx Pharmaceuticals Inc. ( AMLX ) Annual Working Capital Investments ($MM) are -129
Amylyx Pharmaceuticals Inc. ( AMLX ) Book Value ($MM) as of last quarter is 196
Amylyx Pharmaceuticals Inc. ( AMLX ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Amylyx Pharmaceuticals Inc. ( AMLX ) has 71 million in cash on hand as of last quarter
Amylyx Pharmaceuticals Inc. ( AMLX ) has 53 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Amylyx Pharmaceuticals Inc. ( AMLX ) has 68 common shares outstanding as of last quarter
Amylyx Pharmaceuticals Inc. ( AMLX ) has 0 million USD of preferred stock value
Academic Scores:
Amylyx Pharmaceuticals Inc. ( AMLX ) Altman Z-Score is -3.51 as of last quarter
Amylyx Pharmaceuticals Inc. ( AMLX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Amylyx Pharmaceuticals Inc. ( AMLX ) largest shareholder is Geode Capital Management, LLC owning 982068 shares at 4.00 ($MM) value
Bedrosian Camille L(an insider) Sold 5421 shares of Amylyx Pharmaceuticals Inc. ( AMLX ) for the amount of $30007.40 on 2024-12-02
14.32% of Amylyx Pharmaceuticals Inc. ( AMLX ) is held by insiders, and 93.68% is held by institutions
Amylyx Pharmaceuticals Inc. ( AMLX ) went public on 2022-01-07
Other Amylyx Pharmaceuticals Inc. ( AMLX ) financial metrics:
FCF:-95.62
Unlevered Free Cash Flow:0.00
EPS:-4.27
Operating Margin:-18187.74
Gross Profit Margin:-94.47
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-148.22
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Amylyx Pharmaceuticals Inc. ( AMLX ) :
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.